Gilead Sciences, Inc. (GILD) trades at a trailing P/E of 20.5, forward P/E of 16.8. Trailing earnings yield is 4.87%, forward earnings yield 5.96%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $52.99.
Criteria proven by this page:
Overall SharesGrow Score: 78/100 with 6/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 7.1 | -0.38 | 5.08 | 3.16 | 2.56% |
| 2017 | 20.2 | -0.31 | 4.58 | 3.59 | 2.92% |
| 2018 | 14.9 | 0.80 | 3.80 | 3.67 | 3.66% |
| 2019 | 15.3 | 16.09 | 3.66 | 3.68 | 3.90% |
| 2020 | 595.4 | -6.09 | 4.02 | 2.97 | 4.71% |
| 2021 | 14.7 | 0.00 | 4.33 | 3.34 | 3.95% |
| 2022 | 23.5 | -0.90 | 5.07 | 3.95 | 3.44% |
| 2023 | 17.8 | 0.74 | 4.43 | 3.73 | 3.77% |
| 2024 | 240.0 | -2.62 | 5.96 | 4.01 | 3.40% |
| 2025 | 17.9 | 0.01 | 6.75 | 5.19 | 2.62% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $9.94 | $30.39B | $13.5B | 44.4% |
| 2017 | $3.51 | $26.11B | $4.63B | 17.7% |
| 2018 | $4.17 | $22.13B | $5.46B | 24.7% |
| 2019 | $4.22 | $22.45B | $5.39B | 24% |
| 2020 | $0.07 | $24.69B | $123M | 0.5% |
| 2021 | $4.93 | $27.31B | $6.23B | 22.8% |
| 2022 | $3.64 | $27.28B | $4.59B | 16.8% |
| 2023 | $4.50 | $27.12B | $5.67B | 20.9% |
| 2024 | $0.38 | $28.75B | $480M | 1.7% |
| 2025 | $6.78 | $29.44B | $8.51B | 28.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $8.68 | $8.53 – $8.92 | $30.22B | $29.78B – $30.76B | 18 |
| 2027 | $9.66 | $8.28 – $10.70 | $32.08B | $30.76B – $33.53B | 18 |
| 2028 | $10.50 | $8.70 – $11.96 | $33.75B | $33.67B – $33.84B | 9 |
| 2029 | $11.68 | $11.26 – $12.22 | $35.81B | $34.82B – $37.07B | 3 |
| 2030 | $12.67 | $12.21 – $13.25 | $37.7B | $36.65B – $39.02B | 3 |
